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Background. Zinc mediates several vital physiological, enzymatic and cellular functions. The association between serum zinc and
stroke outcome has not been previously evaluated. Methods. This single center retrospective study was conducted on consecutive
stroke (n = 158) and TIA (n = 74) patients. We sought to determine whether serum zinc concentrations in patients with acute
ischemic strokes were associated with stroke severity and poor functional status at discharge, respectively. Results.O v e r a l l ,o u to f
the 224 patients analyzed (mean age 67 years), 35.7% patients had low zinc levels (65mcg/dL). Patients with stroke (n = 152) were
more likely to have low zinc levels (OR = 2.62, CI 1.92–3.57, P<. 003) compared to patients with TIA (n = 72). For patients
with stroke (n = 152), multivariate analysis showed that low serum zinc levels (OR 2.82, CI 1.35–5.91, P = .035) and strokes with
admission severe strokes (NIHSS > 8) (OR 2.68, CI 1.1–6.5, P = .03) were independently associated with poor functional status
(MRS > 3) at discharge from the hospital. Conclusion. Low serum zinc concentrations are associated with more severe strokes on
admission and poor functional status at discharge.
1.Introduction
Zinc is one of the most abundant trace elements in the body.
Second only to iron, it mediates several vital physiological
functions and is essential for maintaining a healthy immune
system and meeting metabolic demands. Preclinical studies
have extensively investigated the role of zinc in cerebral
ischemia [1]. However, whether zinc exerts neuroprotective
or neurotoxic eﬀects during cerebral ischemia is still unclear.
Noclinicalstudyhasinvestigatedanassociationofserum
zinc levels in stroke and transient ischemic attack (TIA).
Mean zinc levels reported in various healthy cohorts range
from 70 ± 32mcg/dL [2] to 105.2mcg/dL [3, 4]. These
levels tend to decrease with age but in diabetics appear
to remain constant throughout life. No signiﬁcant gender
diﬀerences exist in plasma zinc concentrations in healthy
or diabetic individuals [2]. We determined zinc levels in
patientswithTIAandischemicstrokeandexaminedwhether
low zinc levels (≤65mcg/dL) are associated with higher
stroke severity (NIHSS > 8) and poor functional status at
discharge (MRS > 3).
2. Methods
Consecutive patients admitted with a diagnosis of stroke or
TIA between Oct. 2007 and Oct. 2008 were included in this
study. Stroke was deﬁned as evidence of high MRI signal on
diﬀusion weighted imaging (DWI). TIA was deﬁned as focal
neurologicalsymptomslastingforlessthan24hourswithout
evidence of stroke on DWI imaging. All zinc levels were
obtained within 24 hours of admission. Blood samples were
analyzed by atomic absorption spectroscopy; the reference
range was 65–150mcg/dL.
We retrospectively reviewed charts and extracted demo-
graphic data, clinical data, and zinc levels. Based on previous
studies, low zinc levels were deﬁned as ≤65mcg/dL [2–4].
In our population, median zinc levels were 66mcg/dL.
Therefore, we divided zinc levels into two groups: low levels2 Stroke Research and Treatment
Table 1: Demographic characteristics (N = 224).
All patients (n = 224) Ischemic stroke (N = 152) TIA (N = 72)
Mean Age yrs (mean±SD) 67.4 ±16 66.2 ±18 69.1 ±20
Males (N) 112 75 37
Atrial ﬁbrillation (N)6 7 6 0 7
Congestive heart failures (N)1 3 1 12
Coronary artery disease (N)7 2 5 1 2 1
Diabetes mellitus (N)7 5 5 6 1 9
Hypertension (N) 126 80 46
Smoking (N)5 3 4 3 1 0
Dyslipidemia (N) 101 77 24
Admission NIHSS stroke (mean±SD) NA 8 ±6.6N A
Zinc levels (mean±SD) 71 ±26mcg/dL 68 ±29mcg/dL 76 ±18mcg/dL
(≤65mcg/dL) and normal levels (>65mcg/dL or 66mcg/dL
and higher). A severe stroke was deﬁned as (NIHSS > 8).
For patients with stroke, poor functional status at discharge
was deﬁned as (MRS > 3). NIHSS and modiﬁed Rankin
Scales were determined by a neurologist on all patients on
admission (within 1 hour) and on discharge.
SPSS 11.0 was used for data analysis. We also performed
univariate analysis to determine if an association exists
between low zinc levels and factors such as age, sex,
atrial ﬁbrillation, congestive heart failure, coronary artery
disease, hypertension, and stroke severity (NIHSS > 8).
Pearson’s correlation was used to test the general trend of
zinc levels with age. Categorical variables were analyzed
using chi-square and continuous variables were analyzed
using Students’ t-test. T test was used after conﬁrming
a normally distributed data using Q-Q plot. Multivariate
logistic regression analysis was done to evaluate factors
(age, sex, atrial ﬁbrillation, congestive heart faliure, coronary
arterydisease,diabetes,hypertension,andstrokeseverity)on
poor functional discharge status (MRS > 3 versus MRS ≤
3). Statistical signiﬁcance was calculated for 95% CI and
P<. 05.
3. Results
We identiﬁed 232 patients with ischemic stroke or TIA—158
patients (68.1%) had the diagnosis of ischemic stroke and
74 patients (31.9%) patients had the diagnosis of TIA. We
excluded two patients who were on zinc supplements and
6 patients who had medical care withdrawn or died during
the hospitalization. We analyzed a total of 224 patients (152
with stroke and 72 with TIA). Overall, the median zinc
levels were 66mcg/dL. Mean zinc levels (mean ± SD) were
71 ± 26mcg/dL. In patients with stroke, mean NIHSS was
(8±6.6) and median NIHSS was 8. The demographic factors
were similar in patients with TIA and stroke (Table 1).
Overall, 35.7% of patients had low zinc levels
(≤65mcg/dL). Patients with stroke were more likely to have
low zinc levels (OR=2.62, CI 1.92–3.57, P<. 003) compared
to patients with TIA. In patients with stroke, 57.62% patients
had low zinc levels, and 22% of TIA patients had low zinc
levels. We also found a signiﬁcant diﬀerence (P = .032) in
the mean zinc levels in patients with stroke (68±29mcg/dL)
compared to patients with TIA (76 ±28mcg/dL).
In a univariate data analysis of stroke patients, we found
that low zinc levels (OR 2.88, CI 1.31–6.32, chi-square
P = .009) were associated with more severe strokes. Thirty
percent (27 out of 89) of patients with less severe strokes
(NIHSS ≤ 8) and 55.5% patients (35 out of 63) with more
severe strokes (NIHSS > 8) had low zinc levels. Mean zinc
levels in patients with severe strokes (NIHSS > 8) were
signiﬁcantly lower (62 ± 23mcg/dL) (P = .04) compared to
strokes with (NIHSS ≤ 8), (73 ± 15mcg/dL). There were no
diﬀerences in demographic characteristics in patients with
low zinc levels versus normal zinc levels (Table 2).
For patients with stroke (n = 152), we conducted
multivariate logistic regression analysis to adjust for the
eﬀect of factors such as age, sex, HTN, DM, admission
NIHSS, atrial ﬁbrillation, and congestive heart failure on
poor functional status (MRS > 3) at discharge. Our adjusted
analysis showed that only low serum zinc levels (OR 2.82,
CI 1.35–5.91, P = .035) and NIHSS > 8 on admission (OR
2.68, CI 1.1–6.5, P = .03) are independently associated with
poor functional status (MRS > 3) at discharge. Other factors
didnotsigniﬁcantlypredictpoorfunctionaldischargestatus.
Seventy-two percent (39 out of 53) of patients with poor
functional discharge, but only 48.4% (48 out of 99) of
patients with good functional discharge status, had low zinc
levels(chi-squareP value =.008). Additionally, wefoundthat
mean zinc levels in the patients with poor functional status
at discharge (MRS > 3) were 63 ± .29mcg/dL and were
signiﬁcantly lower compared to patients with MRS ≤ 3) at
discharge (73 ±.29mcg/dL) (P = .045).
4. Discussion
Our study is the ﬁrst to show an association between low
zinc levels and cerebral ischemia. Our study showed that
lower zinc levels (≤65mcg/dL) are associated with severe
strokes(NIHSS > 8)andindependentlyassociatedwithpoor
functional status at discharge (MRS > 3).
Preclinical studies have extensively evaluated the role of
zinc in cerebral ischemia and it is still unclear whether zinc
is neurotoxic, neuroprotective, or both [1]. Several of theseStroke Research and Treatment 3
Table 2: Characteristics of patients with Ischemic Stroke and association with Low Zinc levels (≤65mcg/dL).
Total N = 152 Zinc level N = 88
(≤65mcg/dL)
Zinc level N = 64
(>65mcg/dL)
P value#
Mean age yrs
(mean±SD)∗ 66.2 ±18 67.2 ±19 65.2 ±16 P = .62
Males (N) 7 54 43 1 P = .15
Atrial ﬁbrillation (N) 6 03 32 7 P = .32
Congestive heart
failures (N) 11 7 4 P = .11
Coronary artery
disease (N) 51 30 21 P = .18
Diabetes mellitus (N) 5 63 62 0 P = .10
Hypertension (N) 8 05 53 5 P = .15
Smoking (N) 4 32 51 8 P = .40
Dyslipidemia (N) 7 74 13 6 P = .48
Admission (N)
NIHSS stroke >8 63 35 28 P = .32
#All other P values calculated by presence or absence of demographic variable versus percentage of patients with low zinc levels (≤65mcg/dL). T test used for
continuous variables and z test used to test diﬀerences in proportions.
studies evaluating neurotoxic eﬀects,have demonstrated that
elevated intracellular zinc levels [5, 6] and zinc supple-
mentation during cerebral ischemia may enhance neuronal
death [5]. Zinc inhibition achieved through chelation [7–9]
may reduce zinc-mediated neurotoxicity. Conversely, data
supporting the neuroprotective eﬀects of zinc have been
published. Animal-based studies have shown that zinc
supplementation reduces infarct volume [10–12], while zinc
chelation [13] is neurotoxic. Also, zinc is an essential and
integral part of some critical enzyme systems like SOD
(super-oxide dismutase) [14] and matrix metalloproteinases
[15], which may enhance or contribute to tissue injury in
ischemia.
Clinical studies have shown an association between low
zinc levels (≤70mcg/dL) and higher mortality in elderly
patients with pneumonia [16] and higher incidence of
opportunistic infections in AIDS patients with zinc levels
≤65mcg/dL [17]. It has also been shown that zinc levels tend
to fall in myocardial infarction, but the eﬀect on outcomes
after myocardial infarction has not been determined [18].
Zinc supplementation has been shown to improve cancer
survival [19] and promote wound healing [4]. Also, the
value of zinc supplementation [20] and zinc chelation [21]
in stroke patients is safe; however, their role in eﬃcacy is
unclear at this time and may warrant further study. A study
also suggested that low zinc levels may be in fact a risk
factor for stroke [22]. A prevention trial, found that zinc
supplementation in a Chinese cohort of 29584 persons did
not change the rate of stroke death signiﬁcantly (RR 0.99
(0.84–1.18) [23].
Our study does have limitations. Firstly, it is a single-
center study devoid of any normal controls and long-term
outcomes.Inaddition,prestrokefunctionalstatusofpatients
wasunavailable.Thismaybeimportantaspatientswithpoor
nutritional status may have a lower zinc levels and subopti-
mal functional status. However, our analysis was adjusted for
admission NIHSS and discharge MRS, which suggests that
an association of low zinc levels and physical disability exists
in stroke patients. Whether this is related to stroke remains
to be determined. Also, zinc levels are aﬀected by diurnal
variations [24], postprandial and preprandial variations, and
stress. However, our study, for the ﬁrst time, indicates that
lowerserumzinclevelsmaybeassociatedwithstrokeseverity
and extent of disability at discharge. Lower zinc levels were
associated with more severe strokes on admission and with
poor functional status at discharge. As this is an exploratory
study, a large independent epidemiological prospective study
is necessary to delineate the importance of serum zinc levels
in patients with ischemic stroke and to investigate whether
low zinc levels are associated poor long-term outcomes.
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